Associations Between GLP-1 Receptor Agonists and Alopecia: A Multi-Center Retrospective Analysis and Public Interest Trends

This study analyzed data from 393,596 individuals to explore the link between GLP-1 receptor agonists (GLP-1RAs) and alopecia, finding that those using GLP-1RAs had higher odds of developing androgenetic alopecia (AGA) but not alopecia areata (AA) or telogen effluvium (TE). Specific GLP-1RAs like exenatide, dulaglutide, and liraglutide were linked to increased AGA risk, while semaglutide was associated with AGA but not other types of alopecia. Tirzepatide showed no significant alopecia outcomes. Public interest in the connection between GLP-1RAs and hair loss has risen, as indicated by Google Trends. The study calls for further research and advises clinicians to discuss alopecia risks with patients considering GLP-1RA treatment. Limitations include the inability to isolate patients with pre-existing alopecia and the need for prospective studies.